Cardiff Oncology (NASDAQ:CRDF) Releases Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Cardiff Oncology (NASDAQ:CRDF) announced its earnings results on Thursday. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.02, Zacks reports. Cardiff Oncology had a negative return on equity of 103.10% and a negative net margin of 7,885.43%.

Cardiff Oncology Trading Down 3.0%

Shares of NASDAQ:CRDF traded down $0.02 during midday trading on Thursday, reaching $0.74. The company had a trading volume of 236,139 shares, compared to its average volume of 1,027,074. The company’s 50 day moving average price is $1.05 and its 200 day moving average price is $1.37. The stock has a market cap of $57.72 million, a P/E ratio of -1.24 and a beta of 1.57. Cardiff Oncology has a 52-week low of $0.72 and a 52-week high of $3.31.

Analysts Set New Price Targets

Several analysts have recently issued reports on CRDF shares. William Blair lowered shares of Cardiff Oncology from an “outperform” rating to a “market perform” rating in a research note on Tuesday, August 11th. Weiss Ratings raised shares of Cardiff Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday. Wall Street Zen raised shares of Cardiff Oncology from a “strong sell” rating to a “sell” rating in a research report on Saturday, September 5th. Finally, HC Wainwright upgraded shares of Cardiff Oncology from a “neutral” rating to a “buy” rating in a report on Tuesday, September 15th. Three research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $7.50.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc. is a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company’s lead product candidate is onvansertib, an oral, selective inhibitor of polo-like kinase 1 (PLK1), an enzyme involved in cancer-cell division. Cardiff Oncology has primarily evaluated onvansertib in combination with standard treatments for patients with RAS-mutated metastatic colorectal cancer, including investigations involving KRAS-mutated disease. The company has also explored the candidate in other solid tumors, including metastatic castration-resistant prostate cancer.